March 31, 2010 — A blood test may soon be able to identify which patients with multiple sclerosis will and will not respond to beta interferon. Only a reported two-thirds of patients with ...
NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...
October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...
Disease activity despite interferon predicts poor MS outcomes In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes. HealthDay News — ...
medwireNews: The DECIDE study shows that 4-weekly daclizumab high-yield process (HYP) reduces disease activity in patients with relapsing–remitting multiple sclerosis (MS) more effectively than weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results